Fimasartan increases glucose‐stimulated insulin secretion in patients with type 2 diabetes and hypertension compared with amlodipine

• DOI: 10.1111/dom.13282
• Publication Date: 2018-03-16T01:22:53Z
• Authors: Ye Seul Yang; Min Hyuk Lim; Seong Ok Lee; Eun Roh; Chang Ho Ahn; Soo Heon Kwak; Young Min Cho; Sungwan Kim; Andrea Mari; Kyong Soo Park; Hye Seung Jung
• Keywords: Amlodipine; Crossover study; Homeostatic model assessment

Aim To study the effects of angiotensin receptor blockers (ARBs) on insulin secretion in hypertensive patients with type 2 diabetes. Materials and methods A total 41 were enrolled this open‐label, active comparator‐controlled, crossover study. After a 2‐week run‐in period amlodipine, participants assigned to receive either fimasartan (60–120 mg daily) or amlodipine (5–10 for 16 weeks. Thereafter, they treated other drug another Physical examinations laboratory tests performed before after each treatment. Results Blood pressure, glycated haemoglobin oral glucose tolerance test (OGTT) values similar Fimasartan treatment significantly increased median (range) homeostatic assessment β‐cell function (49.9 [22.5–174.4] vs 46.9 [15.6–148.0]), area under curve during OGTT (27 284 [9501–94 525] 26 818 [8112–76 704] pmol/L × min), insulinogenic index at 60 minutes (19.7 [3.0–131.2] 15.0 [2.4–103.8] pmol/mmol) 120 (19.1 [1.9–85.5] 12.6 [−4.3–178.8] compared those (all P < .05); however, acute response resistance indices both agents. Conclusions Compared late‐phase glucose‐stimulated diabetes hypertension. This finding suggests that ARBs would be more beneficial such classes anti‐hypertensives.